Actively Recruiting
Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-21
205
Participants Needed
1
Research Sites
281 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Endoscopic sleeve gastroplasty and bypass are currently available for weight loss in obese patients who have failed nutritional management. Despite very low risks, these techniques remain invasive. What's more, the French National Authority for Health recommends this procedure for patients with a BMI above 35 kg/m² with associated co-morbidities, or above 40 kg/m². This excludes grade I obese patients (30 \< BMI \< 35) who have no effective means of losing weight. The hospital's hepato-gastroenterology and nutrition department has therefore implemented endoscopic sleeve gastroplasty to address this problem. As with other surgical techniques, there is heterogeneity heterogeneity in weight loss. The investigators therefore aim to identify factors predictive of the efficacy of this procedure in order to improve patient management of patients.
CONDITIONS
Official Title
Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient of legal age (Age 218 years)
- Patient capable of understanding the study and signing a consent
- BMI between 30 and 35 kg/m2 with at least one obesity-related complication (diabetes, dyslipidemia, sleep apnea syndrome, non-alcoholic steatohepatitis, joint pain)
- Patients with BMI greater than 35 kg/m2 who have been refused bariatric surgery
- Patient who has failed to lose weight and improve with conventional techniques
- Patient affiliated to a social security scheme
You will not qualify if you...
- Patient having taken antibiotics 3 months prior to inclusion
- Patient under legal protection
- Patient at risk of gastric cancer requiring regular endoscopic surveillance
- Patient with history of gastrointestinal inflammatory disease, hepatic or renal insufficiency, or portal hypertension
- Patient with peptic ulcer disease or progressive peptic ulcer disease
- Patient with pathology affecting general health and/or life expectancy
- Patient with history of bariatric surgery
- Patient on AME
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Antoine Béclère
Paris, France
Actively Recruiting
Research Team
C
Cosmin VOICAN, MD, PhD
CONTACT
G
Gabriel PERLEMUTER, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here